Form 4: Vertex Pharma EVP Reports Routine Stock Transactions

Vertex Pharmaceuticals' EVP and CFO, Charles F. Wagner Jr., reported the acquisition of restricted stock units and the disposition of shares for tax purposes.

Summary

• Charles F. Wagner Jr., Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving the company's common stock.
• On February 17, 2026, Mr. Wagner acquired 7,365 shares of common stock through a restricted stock unit (RSU) award at a price of $0 per share.
• This RSU award is scheduled to vest in installments beginning on February 20, 2027.
• Also on February 17, 2026, Mr. Wagner disposed of 2,294 shares of common stock at a price of $483.75 per share.
• Following these reported transactions, Mr. Wagner's direct beneficial ownership of Vertex Pharmaceuticals common stock stands at 48,786 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The RSU grant is a positive sign of ongoing executive compensation and retention, while the disposition for taxes is a routine, non-discretionary event.

Positives

• The acquisition of 7,365 shares through a restricted stock unit award indicates ongoing executive compensation and alignment of management interests with shareholders.

Negatives

• The disposition of 2,294 shares, likely for tax withholding purposes, represents a reduction in direct beneficial ownership.

Future Outlook

The acquired restricted stock units are scheduled to begin vesting in installments on February 20, 2027, indicating future equity compensation realization for the executive.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and subsequent disposition of shares for tax withholding are standard practices in executive compensation packages across the biotechnology and pharmaceutical industries. These transactions are typically pre-scheduled and non-discretionary, reflecting a common method for aligning executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term shareholder value. The tax-related disposition is a minor, routine event with no significant impact on the broader shareholder base.

Next Steps

• The restricted stock unit award will begin vesting in installments starting on February 20, 2027.

Key Dates

Keywords

VRTX, Vertex Pharmaceuticals, Form 4, Insider Transaction, Restricted Stock Unit, Executive Compensation, Stock Grant, Tax Withholding